ClinicalTrials.gg
CompletedNCT05305547SCORPIO-HRUpdated Aug 20, 2026Results posted

A Study to Compare S-217622 With Placebo in Non-Hospitalized Participants With COVID-19

A Phase 3 interventional study of S-217622 and Placebo in SARS-CoV-2 Infection, sponsored by Shionogi. Completed at 196 sites in 17 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-20.

Sponsored by Shionogi · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
2,093
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 1,859 studies in COVID-19 with a site in United States — 120 open to participants now, 210 under way, 16 of them phase 3. COVID-19 · United States.

Enrollment
110th of 1,321
2,093 · median 91
Started
2022
with 222 others
Phase 3
174 of 1,859
11 open now
Registered
1,430th of 1,859
by date

Among the 1,859 studies in COVID-19 with a site in United States, this one is the 110th largest by enrollment of the 1,321 interventional ones that give a count, is one of 223 that started in 2022, is one of 174 in phase 3, and was the 1,430th registered.

COVID-19

7,994 studies on the registry are indexed under COVID-19; 468 are open to participants now.

Browse COVID-19 studies →

Open to participants now

120 of the 1,859 studies in COVID-19 with a site in United States are open now. Recruiting first, the newest first:

115 more — sign in →

All 120 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 356 COVID-19 studies recruiting now, 206 (58%) set no upper age limit and 83 (23%) stop at 75 or younger; 91 take children under 18; 135 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,859 studies in COVID-19 with a site in United States, or all of them as a file.
02

Study summary

The main aim of this study is to evaluate the efficacy of S-217622 versus placebo among outpatient adults with mild and moderate COVID-19 starting intervention within 3 days of symptom onset.

03

Conditions studied

  • SARS-CoV-2 Infection

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Documentation of laboratory-confirmed active SARS-CoV-2 infection, as determined by a nucleic acid (for example, reverse-transcriptase PCR) or antigen test from any respiratory tract specimen (for example, oropharyngeal, NP or nasal swab, or saliva) collected ≤72 hours (3 days) prior to randomization.
  • Participants are expected to begin study intervention ≤3 days from self-reported date of onset of any of the COVID-19-related symptoms from the following list:
  • Cough
  • Shortness of breath or difficulty breathing
  • Feeling feverish
  • Chills
  • Fatigue
  • Body pain or muscle pain or aches
  • Diarrhea
  • Nausea
  • Vomiting
  • Headache
  • Sore throat
  • Nasal obstruction or congestion
  • Nasal discharge
  • Loss of taste
  • Loss of smell
  • One or more of the following signs/symptoms present within 24 hours prior to randomization:
  • Cough
  • Shortness of breath or difficulty breathing
  • Feeling feverish
  • Chills
  • Fatigue
  • Body pain or muscle pain or aches
  • Diarrhea
  • Nausea
  • Vomiting
  • Headache
  • Sore throat
  • Nasal obstruction or congestion
  • Nasal discharge
  • Participants at higher risk of progression to severe COVID-19 are defined as follows:
  • Age ≥65 years
  • Age ≥18 with 1 of the following:
  • Obesity ( [BMI] ≥30 kilograms per square meter [kg/m\^2]). Note: BMI is rounded to the nearest whole number, for example 29.5 kg/m\^2 is rounded to 30 kg/m\^2.
  • Diabetes mellitus
  • Hypertension requiring daily prescribed therapy
  • Cardiovascular disease (requiring daily prescribed therapy or congenital heart disease)
  • Chronic lung disease (for example, , moderate to severe asthma, interstitial lung disease, cystic fibrosis, pulmonary hypertension) requiring daily prescribed therapy
  • Chronic kidney disease, defined as known current kidney impairment with a (CrCl) or estimated (eGFR) \<60 milliliters (mL)/minute (min)/1.73 square meter (m\^2) within the past 12 months prior to randomization, as long as the participant does not have known CrCl \<30 mL/min by Cockcroft-Gault or require dialysis
  • Down syndrome
  • Sickle cell disease
  • One of the following immunocompromising conditions or treatments:
  • Receiving chemotherapy or other therapies for cancer
  • Hematologic (active or in remission)
  • History of a hematopoietic stem cell or a solid organ transplant
  • infection: not on antiretroviral therapy or with cluster of differentiation 4+ cell count \<200 cells per cubic millimeter
  • Combined primary immunodeficiency disorder
  • Taking immunosuppressive medications (for example, drugs to suppress rejection of transplanted organs or to treat rheumatologic and gastrointestinal conditions, such as anti-tumor necrosis factor agents, mycophenolate, and rituximab).

Note: Current use of some is exclusionary, due to concern for possible drug-drug interaction (DDI) with S-217622.

Exclusion criteria

Exclusion Criteria:

  • History of hospitalization for the current SARS-CoV-2 infection (that is, prior hospitalization for a prior episode of SARS-CoV-2 infection is allowable)
  • For the current SARS-CoV-2 infection, any positive SARS-CoV-2 molecular (nucleic acid) or antigen test from any respiratory tract specimen (for example, oropharyngeal, NP, or nasal swab, or saliva) collected ˃72 hours (3 days) prior to randomization. Participants with reinfection, defined as prior SARS-CoV-2 infection that began >90 days prior to the current onset of symptoms with interval resolution of symptoms are eligible as long as the current infection has not been present for more than 3 days prior to randomization.
  • Current need for hospitalization or immediate medical attention in the opinion of the investigator
  • Current use of any medications prohibited with the study intervention. Individuals who have used Paxlovid or any other oral, inhaled, or injectable medication intended to treat the current SARS-CoV-2 infection before randomization are excluded. After randomization, locally available SARS-CoV-2 treatment (including but not limited to molnupiravir, mAbs, outpatient IV remdesivir, convalescent plasma, inhaled budesonide, favipiravir, and fluvoxamine) will be permitted, as long as there are no concerns for DDIs.

Note: Paxlovid use for a prior episode of COVID-19 is permitted.

  • Receipt of any treatments for the current episode of SARS-CoV-2 at any time prior to randomization is exclusionary. Note: This does not include drugs approved for other uses and taken for those indications or COVID-19 vaccines. Note: Use of locally authorized or approved therapies to prevent COVID-19, such as mAbs given solely to prevent COVID-19, are not exclusionary.
  • Any co-morbidity requiring surgery within 7 days prior to randomization or that is considered life threatening in the opinion of the investigator within 28 days prior to randomization
  • Known allergy/sensitivity or any to components of S-217622 or placebo for S-217622
  • Known (within 12 months prior to randomization) renal impairment defined as \<30 mL/min by Cockcroft-Gault or requiring dialysis
  • Known history of cirrhosis or liver decompensation (including ascites, variceal bleeding, or hepatic encephalopathy)
  • Participants who have used any of the following drugs within 14 days prior to randomization:
  • Strong cytochrome P453A inducer
  • Products containing St. John's Wort
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
2,093 participants (actual)

Study arms

  • Experimental
    S-217622

    S-217622 will be administered orally for 5 days.

    Drug: S-217622

  • Placebo comparator
    Placebo

    Placebo matching to S-217622 will be administered orally for 5 days.

    Drug: Placebo

Interventions

  • Administered as a round tablet.

  • DrugPlacebo

    Administered as a round tablet.

06

What researchers measure

Primary outcomes

  1. Time to Sustained Symptom Resolution

    Time to sustained symptom resolution was defined as the time from start of study intervention to the first day of 2 consecutive days with complete resolution of COVID-19 symptoms on participant self-assessment and alive and without hospitalization for any reason by Day 29. Hospitalization was defined as ≥24 hours of acute care in a hospital or similar acute care facility, including emergency rooms, urgent care clinics, or facilities instituted to address medical needs of those with COVID-19.

    Time frame: Up to Day 29

Secondary outcomes

  1. Change From Baseline at Day 4 in Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) RNA Levels on Nasopharyngeal (NP) Swabs

    NP swabs were collected by staff during in-person visits for measurement of SARS-CoV-2 RNA levels by quantitative log10 polymerase chain reaction (PCR). Results reported as log10 (RNA copies/milliliter \[mL\]).

    Time frame: Baseline, Day 4

  2. Number of Participants Who Experienced Hospitalization (Adjudicated) or Death Due to Any Cause

    Hospitalization was defined as ≥24 hours of acute care in a hospital or similar acute care facility, including emergency rooms, urgent care clinics, or facilities instituted to address medical needs of those with COVID-19. Hospitalization was adjudicated to be COVID-19-related. All deaths regardless of occurrence outside of hospital or during hospitalization (not adjudicated) are reported.

    Time frame: Up to Day 29

  3. Time to Sustained Symptom Resolution in the mITT1 Set

    Time to sustained symptom resolution was defined as the time from start of study intervention to the first day of 2 consecutive days with complete resolution of COVID-19 symptoms on participant self-assessment and alive and without hospitalization for any reason by Day 29. Hospitalization was defined as ≥24 hours of acute care in a hospital or similar acute care facility, including emergency rooms, urgent care clinics, or facilities instituted to address medical needs of those with COVID-19. Wald confidence interval reported.

    Time frame: Up to Day 29

  4. Median Change From Baseline at Day 8 in SARS-CoV-2 RNA Levels on NP Swabs

    NP swabs were collected by staff during in-person visits for measurement of SARS-CoV-2 RNA levels by quantitative log10 PCR.

    Time frame: Baseline, Day 8

  5. Number of Participants With Persistent and/or Late-Onset Symptoms of COVID-19 at Week 12

    The number of participants with persistent and/or late-onset symptoms of COVID-19 at Week 12 based on participant assessment of the 5 symptoms specified by the World Health Organization (WHO) (fatigue, shortness of breath/difficulty breathing, difficulty with concentration/ thinking, difficulty reasoning/solving problems, and memory loss) plus taste disturbance and smell disturbance.

    Time frame: Week 12

  6. Time to Sustained Resolution of 6 Targeted Symptoms and Being Alive and Without Hospitalization for Any Reason by Day 29

    The time to sustained symptom resolution was defined as the first day of 2 consecutive days with complete resolution of COVID-19 symptoms on participant self-assessment and being alive and without hospitalization for any reason by Day 29. Data are reported for time (days) from start of ensitrelvir or placebo (Day 1) until sustained resolution based on assessments for 2 consecutive days of 6 targeted symptoms (nasal obstruction or congestion, nasal discharge, sore throat, cough, feeling feverish, and fatigue) and being alive and not hospitalized for any reason. Hospitalization was defined as ≥24 hours of acute care in a hospital or similar acute care facility, including emergency rooms, urgent care clinics, or facilities instituted to address medical needs of those with COVID-19.

    Time frame: Day 1 through Day 29

  7. Time to Sustained Resolution of Targeted Symptoms (Excluding Loss of Taste and Loss of Smell) and Being Alive and Without Hospitalization for Any Reason by Day 29

    The time to sustained symptom resolution was defined as the first day of 2 consecutive days with complete resolution of COVID-19 symptoms on participant self-assessment and being alive and without hospitalization for any reason by Day 29. Time (days) from start of ensitrelvir or placebo (Day 1) until sustained resolution (where cough and fatigue were considered resolved if they remain mild) based on assessments for 2 consecutive days of all targeted symptoms excluding loss of taste and loss of smell (cough, shortness of breath or difficulty breathing, feeling feverish, chills, fatigue, body pain or muscle pain or aches, diarrhea, nausea, vomiting, headache, sore throat, nasal obstruction or congestion, and nasal discharge) and being alive and not hospitalized for any reason by Day 29. Hospitalization was ≥24 hours of acute care, in a hospital or similar acute care facility (emergency rooms, urgent care clinics, or facilities instituted to address medical needs of those with COVID-19).

    Time frame: Day 1 through Day 29

  8. Number of Participants With Undetectable SARS-CoV-2 on NP Swabs on Day 4 and Day 8

    NP swabs were collected by staff during in-person visits for measurement of SARS-CoV-2 RNA levels by viral titer by culture.

    Time frame: Day 4 and Day 8

  9. Number of Participants Experiencing Hospitalization (All Cause) or Death Due to Any Cause

    Hospitalization was defined as ≥24 hours of acute care in a hospital or similar acute care facility, including emergency rooms, urgent care clinics, or facilities instituted to address medical needs. All deaths regardless of occurrence outside of hospital or during hospitalization (not adjudicated) are reported.

    Time frame: Up to Day 29

  10. Number of Participants With NP SARS-CoV-2 RNA Levels Below the Lower Limit of Quantification on Day 4 and Day 8

    NP swabs were collected by staff during in-person visits for measurement of SARS-CoV-2 RNA levels by log10 quantitative PCR.

    Time frame: Day 4 and Day 8

  11. Median Change From Baseline at Day 4 and Day 8 in SARS-CoV-2 RNA by Quantitative PCR in NP Swabs

    NP swabs were collected by staff during in-person visits per protocol for measurement of log10 SARS-CoV-2 RNA levels by quantitative PCR.

    Time frame: Baseline, Day 4, Day 8

  12. Time to Self-Reported Return to Usual (Pre-COVID-19) Health

    Participants kept a log of symptoms and major events in their study diary. The time to self-reported return to health (in days) was derived as: (the date of self-reported return to usual \[pre-COVID-19 health\] - (the date of first dose of study intervention) + 1.

    Time frame: Day 1 up to Day 29

  13. Number of Participants Reaching a Score ≥2, ≥3, ≥4, ≥5, ≥6, ≥7, or ≥8 on the WHO Ordinal Scale

    The severity of COVID-19 disease was assessed using the WHO ordinal scale. The scale ranged from 1 to 8 and focuses primarily on the participant's oxygen need when they first came to the hospital. Scores include: 1 = no limitation of activities; 2 = limitation of activities; 3 = hospitalized no oxygen therapy; 4 = oxygen by mask or nasal prongs; 5 = non-invasive ventilation or high flow oxygen; 6 = intubation and mechanical ventilation; 7 = ventilation and additional organ support, pressors, renal replacement therapy, extra corporeal membrane oxygenation; 8 = death. Higher scores indicated greater severity of illness and a need for more intensive medical support.

    Time frame: Day 29

  14. Change From Baseline at Day 29 in Resting Peripheral Oxygen Saturation

    Resting peripheral oxygen saturation was measured as the percentage of oxygen transported throughout the participant's body. An increase in percentage indicated an increased oxygen supply throughout the body.

    Time frame: Baseline, Day 29

  15. Number of Participants With Resting Peripheral Oxygen Saturation <96% Versus ≥96%

    Resting peripheral oxygen saturation was measured as the percentage of oxygen transported throughout the participant's body. Saturation levels at ≥96% indicated effective oxygen transportation throughout the body. A decrease in percentage indicated decreased oxygen supply throughout the body.

    Time frame: Up to Day 29

  16. Severity of Persistent and/or Late-Onset Symptoms of COVID-19 at Week 24

    A participant was considered to have persistent and/or late-onset symptoms if either 1 of the following criteria was met: occurrence of at least 1 of the following symptoms at Week 24: difficulty with concentration/thinking, difficulty reasoning/solving problems, or memory loss; or occurrence of at least 1 of the following symptoms at Week 24: fatigue, shortness of breath/difficulty breathing, taste disturbance, or smell disturbance. Symptom severity assessed as: None; Mild; Moderate; Severe; At least Mild.

    Time frame: Week 24

  17. Number of Participants With Symptomatic Viral Rebound Between Day 6 and Day 29

    NP swabs were collected by staff during in-person visits for measurement of SARS-CoV-2 RNA levels by log10 quantitative PCR. Symptomatic viral rebound was defined as an increase in NP SARS-CoV-2 RNA levels by quantitative PCR or an increase in NP SARS-CoV-2 viral culture.

    Time frame: Day 6 up to Day 29

  18. Number of Participants With Viral Rebound Between Day 6 and Day 29

    NP swabs were collected by staff during in-person visits for measurement of SARS-CoV-2 RNA levels by quantitative PCR. Viral rebound was defined as an increase in quantitative NP SARS-CoV-2 viral culture or NP SARS CoV-2 RNA levels by quantitative PCR.

    Time frame: Day 6 up to Day 29

  19. Change From Baseline at Week 24 in Short Form 36 Version 2.0 (SF-36 V2) Quality of Life Score

    The SF-36v2 is a 36-item, participant-reported survey of participant health that measures 8 scales: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role emotional, and mental health. Each component was directly transformed into a 0 to 100 scale on the assumption that each question carried equal weight. A score of 0 was equal to maximum disability, and a score of 100 indicated no disability. Mean change could range from -100 to 100. A positive mean change indicated an improved outcome.

    Time frame: Baseline, Week 24

  20. Change From Baseline at Week 24 in EuroQol-5 Dimension 5 Level (EQ-5D-5L): Visual Analog Scale (VAS)

    The EQ-5D-5L VAS is an instrument for self-reported assessment that ranks participant health status. Participants self-rate their health status using a scale of best health imaginable (100) to worst health imaginable (0). An increase in score indicates an improved health status.

    Time frame: Baseline, Week 24

  21. Number of Participants With a Response as Measured by the Post-Acute COVID-19 Questionnaire

    Participants completed a post-acute COVID-19 questionnaire at each scheduled visit. The questionnaire is a survey instrument used to help measure functional health and health-related quality of life post-acute COVID-19. One of the items the questionnaire captures was whether the participant sought urgent medical care at an emergency room or clinic for specified symptoms (answered 'Yes' or 'No'). Symptoms ranged from cough and shortness of breath or difficult breathing to difficulty reasoning and solving problems and memory loss (short or long term). The number of participants answering 'Yes' to this question is reported.

    Time frame: Week 24

  22. Number of Participants Who Experienced Death Due to Any Cause

    All participants in the mITT set who experienced death due to any cause are reported. All deaths regardless of occurrence outside of hospital or during hospitalization (not adjudicated) are reported.

    Time frame: Baseline through Week 24

  23. Plasma Concentration of Ensitrelvir at Day 4

    Plasma samples were collected at specified timepoints to measure ensitrelvir levels. Results reported as micrograms/milliliter (ug/mL).

    Time frame: Day 4 (up to 90 minutes postdose)

07

Results

Posted Aug 20, 2026

Participant flow

Participant flow — Overall Study
MilestoneEnsitrelvirPlacebo
Started10421051
Received at least 1 dose of study drug10381047
Modified intent-to-treat (mitt) set945943
Viral culture set309292
Safety analysis set10371048
Pharmacokinetic (pk) set22265
Completed980994
Not completed6257
Withdrew: Sponsor decision42
Withdrew: Physician decision23
Withdrew: Lost to follow-up2525
Withdrew: Death02
Withdrew: Adverse event11
Withdrew: Other than specified76
Withdrew: Withdrawal by subject2318

Outcome measures

PrimaryTime to Sustained Symptom Resolution

Time to sustained symptom resolution was defined as the time from start of study intervention to the first day of 2 consecutive days with complete resolution of COVID-19 symptoms on participant self-assessment and alive and without hospitalization for any reason by Day 29. Hospitalization was defined as ≥24 hours of acute care in a hospital or similar acute care facility, including emergency rooms, urgent care clinics, or facilities instituted to address medical needs of those with COVID-19.

Time frame:
Up to Day 29
Reported as:
Mean · days
Time to Sustained Symptom Resolution
daysEnsitrelvirPlacebo
Time to Sustained Symptom Resolution12.5 (11.97 to 13.08)13.1 (12.56 to 13.68)
Statistical analysis
  • Ensitrelvir vs Placebo · t-test, 2 sided · p = 0.1397 · Mean difference: -0.6 · 95% CI -1.38 to 0.19Difference in restricted mean symptom duration compares the time (days) from the start of intervention to sustained resolution.
SecondaryChange From Baseline at Day 4 in Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) RNA Levels on Nasopharyngeal (NP) Swabs

NP swabs were collected by staff during in-person visits for measurement of SARS-CoV-2 RNA levels by quantitative log10 polymerase chain reaction (PCR). Results reported as log10 (RNA copies/milliliter \[mL\]).

Time frame:
Baseline, Day 4
Reported as:
Mean · log10 (RNA copies/mL)
Change From Baseline at Day 4 in Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) RNA Levels on Nasopharyngeal (NP) Swabs
log10 (RNA copies/mL)EnsitrelvirPlacebo
Change From Baseline at Day 4 in Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) RNA Levels on Nasopharyngeal (NP) Swabs-2.7435 ± 2.09428-1.9630 ± 2.07001
SecondaryNumber of Participants Who Experienced Hospitalization (Adjudicated) or Death Due to Any Cause

Hospitalization was defined as ≥24 hours of acute care in a hospital or similar acute care facility, including emergency rooms, urgent care clinics, or facilities instituted to address medical needs of those with COVID-19. Hospitalization was adjudicated to be COVID-19-related. All deaths regardless of occurrence outside of hospital or during hospitalization (not adjudicated) are reported.

Time frame:
Up to Day 29
Reported as:
Count of participants · Participants
Number of Participants Who Experienced Hospitalization (Adjudicated) or Death Due to Any Cause
ParticipantsEnsitrelvirPlacebo
mITT31
mITT131
SecondaryTime to Sustained Symptom Resolution in the mITT1 Set

Time to sustained symptom resolution was defined as the time from start of study intervention to the first day of 2 consecutive days with complete resolution of COVID-19 symptoms on participant self-assessment and alive and without hospitalization for any reason by Day 29. Hospitalization was defined as ≥24 hours of acute care in a hospital or similar acute care facility, including emergency rooms, urgent care clinics, or facilities instituted to address medical needs of those with COVID-19. Wald confidence interval reported.

Time frame:
Up to Day 29
Reported as:
Mean · days
Time to Sustained Symptom Resolution in the mITT1 Set
daysEnsitrelvirPlacebo
Time to Sustained Symptom Resolution in the mITT1 Set12.6 (12.03 to 13.09)13.1 (12.62 to 13.68)
SecondaryMedian Change From Baseline at Day 8 in SARS-CoV-2 RNA Levels on NP Swabs

NP swabs were collected by staff during in-person visits for measurement of SARS-CoV-2 RNA levels by quantitative log10 PCR.

Time frame:
Baseline, Day 8
Reported as:
Median · log10 (RNA copies/mL)
Median Change From Baseline at Day 8 in SARS-CoV-2 RNA Levels on NP Swabs
log10 (RNA copies/mL)EnsitrelvirPlacebo
Median Change From Baseline at Day 8 in SARS-CoV-2 RNA Levels on NP Swabs-4.6000 (-5.6905 to -2.4450)-4.1710 (-5.3300 to -2.2550)
SecondaryNumber of Participants With Persistent and/or Late-Onset Symptoms of COVID-19 at Week 12

The number of participants with persistent and/or late-onset symptoms of COVID-19 at Week 12 based on participant assessment of the 5 symptoms specified by the World Health Organization (WHO) (fatigue, shortness of breath/difficulty breathing, difficulty with concentration/ thinking, difficulty reasoning/solving problems, and memory loss) plus taste disturbance and smell disturbance.

Time frame:
Week 12
Reported as:
Count of participants · Participants
Number of Participants With Persistent and/or Late-Onset Symptoms of COVID-19 at Week 12
ParticipantsEnsitrelvirPlacebo
Week 12: mITT227221
Week 12: mITT1256253
SecondaryTime to Sustained Resolution of 6 Targeted Symptoms and Being Alive and Without Hospitalization for Any Reason by Day 29

The time to sustained symptom resolution was defined as the first day of 2 consecutive days with complete resolution of COVID-19 symptoms on participant self-assessment and being alive and without hospitalization for any reason by Day 29. Data are reported for time (days) from start of ensitrelvir or placebo (Day 1) until sustained resolution based on assessments for 2 consecutive days of 6 targeted symptoms (nasal obstruction or congestion, nasal discharge, sore throat, cough, feeling feverish, and fatigue) and being alive and not hospitalized for any reason. Hospitalization was defined as ≥24 hours of acute care in a hospital or similar acute care facility, including emergency rooms, urgent care clinics, or facilities instituted to address medical needs of those with COVID-19.

Time frame:
Day 1 through Day 29
Reported as:
Mean · days
Time to Sustained Resolution of 6 Targeted Symptoms and Being Alive and Without Hospitalization for Any Reason by Day 29
daysEnsitrelvirPlacebo
Time to Sustained Resolution of 6 Targeted Symptoms and Being Alive and Without Hospitalization for Any Reason by Day 2911.3 (10.75 to 11.82)12.0 (11.45 to 12.56)
SecondaryTime to Sustained Resolution of Targeted Symptoms (Excluding Loss of Taste and Loss of Smell) and Being Alive and Without Hospitalization for Any Reason by Day 29

The time to sustained symptom resolution was defined as the first day of 2 consecutive days with complete resolution of COVID-19 symptoms on participant self-assessment and being alive and without hospitalization for any reason by Day 29. Time (days) from start of ensitrelvir or placebo (Day 1) until sustained resolution (where cough and fatigue were considered resolved if they remain mild) based on assessments for 2 consecutive days of all targeted symptoms excluding loss of taste and loss of smell (cough, shortness of breath or difficulty breathing, feeling feverish, chills, fatigue, body pain or muscle pain or aches, diarrhea, nausea, vomiting, headache, sore throat, nasal obstruction or congestion, and nasal discharge) and being alive and not hospitalized for any reason by Day 29. Hospitalization was ≥24 hours of acute care, in a hospital or similar acute care facility (emergency rooms, urgent care clinics, or facilities instituted to address medical needs of those with COVID-19).

Time frame:
Day 1 through Day 29
Reported as:
Mean · days
Time to Sustained Resolution of Targeted Symptoms (Excluding Loss of Taste and Loss of Smell) and Being Alive and Without Hospitalization for Any Reason by Day 29
daysEnsitrelvirPlacebo
Time to Sustained Resolution of Targeted Symptoms (Excluding Loss of Taste and Loss of Smell) and Being Alive and Without Hospitalization for Any Reason by Day 2912.2 (11.61 to 12.72)12.8 (12.20 to 13.32)
SecondaryNumber of Participants With Undetectable SARS-CoV-2 on NP Swabs on Day 4 and Day 8

NP swabs were collected by staff during in-person visits for measurement of SARS-CoV-2 RNA levels by viral titer by culture.

Time frame:
Day 4 and Day 8
Reported as:
Count of participants · Participants
Number of Participants With Undetectable SARS-CoV-2 on NP Swabs on Day 4 and Day 8
ParticipantsEnsitrelvirPlacebo
Day 4274210
Day 8283267
SecondaryNumber of Participants Experiencing Hospitalization (All Cause) or Death Due to Any Cause

Hospitalization was defined as ≥24 hours of acute care in a hospital or similar acute care facility, including emergency rooms, urgent care clinics, or facilities instituted to address medical needs. All deaths regardless of occurrence outside of hospital or during hospitalization (not adjudicated) are reported.

Time frame:
Up to Day 29
Reported as:
Count of participants · Participants
Number of Participants Experiencing Hospitalization (All Cause) or Death Due to Any Cause
ParticipantsEnsitrelvirPlacebo
Number of Participants Experiencing Hospitalization (All Cause) or Death Due to Any Cause32
SecondaryNumber of Participants With NP SARS-CoV-2 RNA Levels Below the Lower Limit of Quantification on Day 4 and Day 8

NP swabs were collected by staff during in-person visits for measurement of SARS-CoV-2 RNA levels by log10 quantitative PCR.

Time frame:
Day 4 and Day 8
Reported as:
Count of participants · Participants
Number of Participants With NP SARS-CoV-2 RNA Levels Below the Lower Limit of Quantification on Day 4 and Day 8
ParticipantsEnsitrelvirPlacebo
Day 4415345
Day 8707666
SecondaryMedian Change From Baseline at Day 4 and Day 8 in SARS-CoV-2 RNA by Quantitative PCR in NP Swabs

NP swabs were collected by staff during in-person visits per protocol for measurement of log10 SARS-CoV-2 RNA levels by quantitative PCR.

Time frame:
Baseline, Day 4, Day 8
Reported as:
Median · log10 (RNA copies/mL)
Median Change From Baseline at Day 4 and Day 8 in SARS-CoV-2 RNA by Quantitative PCR in NP Swabs
log10 (RNA copies/mL)EnsitrelvirPlacebo
Day 4-1.250 (-4.50 to 3.00)-1.000 (-5.00 to 3.00)
Day 8-1.250 (-5.00 to -.025)-1.000 (-5.00 to 0.50)
SecondaryTime to Self-Reported Return to Usual (Pre-COVID-19) Health

Participants kept a log of symptoms and major events in their study diary. The time to self-reported return to health (in days) was derived as: (the date of self-reported return to usual \[pre-COVID-19 health\] - (the date of first dose of study intervention) + 1.

Time frame:
Day 1 up to Day 29
Reported as:
Mean · days
Time to Self-Reported Return to Usual (Pre-COVID-19) Health
daysEnsitrelvirPlacebo
Time to Self-Reported Return to Usual (Pre-COVID-19) Health11.4 (10.83 to 11.93)11.9 (11.37 to 12.50)
SecondaryNumber of Participants Reaching a Score ≥2, ≥3, ≥4, ≥5, ≥6, ≥7, or ≥8 on the WHO Ordinal Scale

The severity of COVID-19 disease was assessed using the WHO ordinal scale. The scale ranged from 1 to 8 and focuses primarily on the participant's oxygen need when they first came to the hospital. Scores include: 1 = no limitation of activities; 2 = limitation of activities; 3 = hospitalized no oxygen therapy; 4 = oxygen by mask or nasal prongs; 5 = non-invasive ventilation or high flow oxygen; 6 = intubation and mechanical ventilation; 7 = ventilation and additional organ support, pressors, renal replacement therapy, extra corporeal membrane oxygenation; 8 = death. Higher scores indicated greater severity of illness and a need for more intensive medical support.

Time frame:
Day 29
Reported as:
Count of participants · Participants
Number of Participants Reaching a Score ≥2, ≥3, ≥4, ≥5, ≥6, ≥7, or ≥8 on the WHO Ordinal Scale
ParticipantsEnsitrelvirPlacebo
Score of ≥21517
Score of ≥310
Score of ≥400
Score of ≥500
Score of ≥600
Score of ≥700
Score of ≥800
SecondaryChange From Baseline at Day 29 in Resting Peripheral Oxygen Saturation

Resting peripheral oxygen saturation was measured as the percentage of oxygen transported throughout the participant's body. An increase in percentage indicated an increased oxygen supply throughout the body.

Time frame:
Baseline, Day 29
Reported as:
Mean · percentage of oxygen
Change From Baseline at Day 29 in Resting Peripheral Oxygen Saturation
percentage of oxygenEnsitrelvirPlacebo
Change From Baseline at Day 29 in Resting Peripheral Oxygen Saturation0.7 ± 1.570.8 ± 1.48
SecondaryNumber of Participants With Resting Peripheral Oxygen Saturation <96% Versus ≥96%

Resting peripheral oxygen saturation was measured as the percentage of oxygen transported throughout the participant's body. Saturation levels at ≥96% indicated effective oxygen transportation throughout the body. A decrease in percentage indicated decreased oxygen supply throughout the body.

Time frame:
Up to Day 29
Reported as:
Count of participants · Participants
Number of Participants With Resting Peripheral Oxygen Saturation <96% Versus ≥96%
ParticipantsEnsitrelvirPlacebo
Oxygen Saturation <96%2824
Oxygen Saturation ≥96%846843
SecondarySeverity of Persistent and/or Late-Onset Symptoms of COVID-19 at Week 24

A participant was considered to have persistent and/or late-onset symptoms if either 1 of the following criteria was met: occurrence of at least 1 of the following symptoms at Week 24: difficulty with concentration/thinking, difficulty reasoning/solving problems, or memory loss; or occurrence of at least 1 of the following symptoms at Week 24: fatigue, shortness of breath/difficulty breathing, taste disturbance, or smell disturbance. Symptom severity assessed as: None; Mild; Moderate; Severe; At least Mild.

Time frame:
Week 24
Reported as:
Count of participants · Participants
Severity of Persistent and/or Late-Onset Symptoms of COVID-19 at Week 24
ParticipantsEnsitrelvirPlacebo
None (mITT)545537
Mild (mITT)1526
Moderate (mITT)73
Severe (mITT)13
At Least Mild (mITT)2332
None (mITT1)619611
Mild (mITT1)1830
Moderate (mITT1)73
Severe (mITT1)1465
At Least Mild (mITT1)2637
SecondaryNumber of Participants With Symptomatic Viral Rebound Between Day 6 and Day 29

NP swabs were collected by staff during in-person visits for measurement of SARS-CoV-2 RNA levels by log10 quantitative PCR. Symptomatic viral rebound was defined as an increase in NP SARS-CoV-2 RNA levels by quantitative PCR or an increase in NP SARS-CoV-2 viral culture.

Time frame:
Day 6 up to Day 29
Reported as:
Count of participants · Participants
Number of Participants With Symptomatic Viral Rebound Between Day 6 and Day 29
ParticipantsEnsitrelvirPlacebo
Viral Culture: mITT00
Quantitative PCR: mITT00
Viral Culture: mITT100
Quantitative PCR: mITT100
SecondaryNumber of Participants With Viral Rebound Between Day 6 and Day 29

NP swabs were collected by staff during in-person visits for measurement of SARS-CoV-2 RNA levels by quantitative PCR. Viral rebound was defined as an increase in quantitative NP SARS-CoV-2 viral culture or NP SARS CoV-2 RNA levels by quantitative PCR.

Time frame:
Day 6 up to Day 29
Reported as:
Count of participants · Participants
Number of Participants With Viral Rebound Between Day 6 and Day 29
ParticipantsEnsitrelvirPlacebo
Viral Culture: mITT613
Quantitative PCR: mITT2321
Viral Culture: mITT1713
Quantitative PCR: mITT12423
SecondaryChange From Baseline at Week 24 in Short Form 36 Version 2.0 (SF-36 V2) Quality of Life Score

The SF-36v2 is a 36-item, participant-reported survey of participant health that measures 8 scales: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role emotional, and mental health. Each component was directly transformed into a 0 to 100 scale on the assumption that each question carried equal weight. A score of 0 was equal to maximum disability, and a score of 100 indicated no disability. Mean change could range from -100 to 100. A positive mean change indicated an improved outcome.

Time frame:
Baseline, Week 24
Reported as:
Mean · units on a scale
Change From Baseline at Week 24 in Short Form 36 Version 2.0 (SF-36 V2) Quality of Life Score
units on a scaleEnsitrelvirPlacebo
Physical Functioning22.447 ± 26.726422.331 ± 26.7551
Role Physical12.831 ± 25.264214.926 ± 25.8196
Bodily Pain20.112 ± 25.745920.316 ± 25.1820
General Health16.367 ± 19.653615.985 ± 19.5233
Vitality10.324 ± 20.877010.905 ± 20.8562
Social Functioning10.485 ± 24.06579.193 ± 23.2424
Role Emotional6.853 ± 23.19997.682 ± 23.9112
Mental Health7.159 ± 20.00927.401 ± 19.2495
SecondaryChange From Baseline at Week 24 in EuroQol-5 Dimension 5 Level (EQ-5D-5L): Visual Analog Scale (VAS)

The EQ-5D-5L VAS is an instrument for self-reported assessment that ranks participant health status. Participants self-rate their health status using a scale of best health imaginable (100) to worst health imaginable (0). An increase in score indicates an improved health status.

Time frame:
Baseline, Week 24
Reported as:
Mean · units on a Scale
Change From Baseline at Week 24 in EuroQol-5 Dimension 5 Level (EQ-5D-5L): Visual Analog Scale (VAS)
units on a ScaleEnsitrelvirPlacebo
Change From Baseline at Week 24 in EuroQol-5 Dimension 5 Level (EQ-5D-5L): Visual Analog Scale (VAS)26.4 ± 17.3524.6 ± 17.30
SecondaryNumber of Participants With a Response as Measured by the Post-Acute COVID-19 Questionnaire

Participants completed a post-acute COVID-19 questionnaire at each scheduled visit. The questionnaire is a survey instrument used to help measure functional health and health-related quality of life post-acute COVID-19. One of the items the questionnaire captures was whether the participant sought urgent medical care at an emergency room or clinic for specified symptoms (answered 'Yes' or 'No'). Symptoms ranged from cough and shortness of breath or difficult breathing to difficulty reasoning and solving problems and memory loss (short or long term). The number of participants answering 'Yes' to this question is reported.

Time frame:
Week 24
Reported as:
Count of participants · Participants
Number of Participants With a Response as Measured by the Post-Acute COVID-19 Questionnaire
ParticipantsEnsitrelvirPlacebo
Number of Participants With a Response as Measured by the Post-Acute COVID-19 Questionnaire2521
SecondaryNumber of Participants Who Experienced Death Due to Any Cause

All participants in the mITT set who experienced death due to any cause are reported. All deaths regardless of occurrence outside of hospital or during hospitalization (not adjudicated) are reported.

Time frame:
Baseline through Week 24
Reported as:
Count of participants · Participants
Number of Participants Who Experienced Death Due to Any Cause
ParticipantsEnsitrelvirPlacebo
Number of Participants Who Experienced Death Due to Any Cause02
SecondaryPlasma Concentration of Ensitrelvir at Day 4

Plasma samples were collected at specified timepoints to measure ensitrelvir levels. Results reported as micrograms/milliliter (ug/mL).

Time frame:
Day 4 (up to 90 minutes postdose)
Reported as:
Mean · ug/mL
Plasma Concentration of Ensitrelvir at Day 4
ug/mLEnsitrelvir
Plasma Concentration of Ensitrelvir at Day 468.492 ± 170.6613

Adverse events

Collected over Day 1 through Week 24. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Ensitrelvir0/1,037 (0%)11/1,037 (1.1%)472/1,037 (45.5%)
Placebo2/1,048 (0.2%)13/1,048 (1.2%)474/1,048 (45.2%)
Most frequent serious events
Showing 10 of 28
Most frequent serious events
EventEnsitrelvirPlacebo
Lower respiratory tract infectionInfections and infestations0/10372/1048
Abortion spontaneousPregnancy, puerperium and perinatal conditions0/5871/568
EndometriosisReproductive system and breast disorders0/5871/568
AppendicitisInfections and infestations1/10371/1048
PneumoniaInfections and infestations1/10370/1048
Anal fistulaGastrointestinal disorders1/10370/1048
Idiopathic pancreatitisGastrointestinal disorders1/10370/1048
Hepatic enzyme increasedInvestigations1/10370/1048
Lymphocyte count decreasedInvestigations1/10370/1048
Cerebral atrophyNervous system disorders1/10370/1048
Most frequent other events
Most frequent other events
EventEnsitrelvirPlacebo
HypertriglyceridaemiaMetabolism and nutrition disorders167/1037154/1048
Creatinine renal clearance decreasedInvestigations111/1037101/1048
Blood triglycerides increasedInvestigations107/103798/1048
HyperglycaemiaMetabolism and nutrition disorders93/103792/1048
Low density lipoprotein increasedInvestigations78/103784/1048
HeadacheNervous system disorders40/103759/1048
Blood glucose increasedInvestigations46/103758/1048
Alanine aminotransferase increasedInvestigations38/103758/1048

Baseline characteristics

Modified Intent-to-treat (mITT) Set: all randomized participants who took at least 1 dose of ensitrelvir or placebo and who started intervention within 3 days of symptom onset.

Age, Continuous
Age, Continuous(years)EnsitrelvirPlaceboTotal
Mean40.4 ± 13.6840.1 ± 13.8040.3 ± 13.74
Sex: Female, Male
Sex: Female, Male(Participants)EnsitrelvirPlaceboTotal
Female5405061046
Male405437842
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)EnsitrelvirPlaceboTotal
Hispanic or Latino430421851
Not Hispanic or Latino5085111019
Unknown or Not Reported71118
Race (NIH/OMB)
Race (NIH/OMB)(Participants)EnsitrelvirPlaceboTotal
American Indian or Alaska Native9514
Asian387396783
Native Hawaiian or Other Pacific Islander000
Black or African American7792169
White403383786
More than one race538
Unknown or Not Reported6464128
Coronavirus Disease 2019 (COVID-19) Vaccination Status
Coronavirus Disease 2019 (COVID-19) Vaccination Status(Participants)EnsitrelvirPlaceboTotal
Not vaccinated245208453
Completed primary series with last vaccine >3 months prior to enrollment6757141389
Completed primary series with last vaccine ≤3 months prior to enrollment211839
Missing437
08

Study locations

196 sites
  • Lakeview Clinical Research
    Guntersville, Alabama 35976, United States
  • Voyage Medical Services
    Tempe, Arizona 85282, United States
  • Novak Clinical Research
    Tucson, Arizona 85741, United States
  • Hope Clinical Research
    Canoga Park, California 91303, United States
  • Carbon Health
    Culver City, California 91606, United States
  • NICR
    Garden Grove, California 92866, United States
  • Ark Clinical Research (PARENT)
    Long Beach, California 94110, United States
  • UCSD Antiviral Research Center
    San Diego, California 92103, United States
  • University of California San Francisco (PARENT)
    San Francisco, California 94110, United States
  • Clinical Trials Management Services, 223 E. Thousand Oaks Blvd.
    Thousand Oaks, California 91360, United States
  • Lundquist Institute for BMI, UCLA Medical Center
    Torrance, California 90502, United States
  • University of Colorado Anschutz Medical Campus
    Aurora, Colorado 80045, United States
  • Whitman-Walker Health
    Washington D.C., District of Columbia 20005, United States
  • University of Florida Clinical & Translational Science Institute
    Gainesville, Florida 32610, United States
  • Universal Medical and Research Center
    Miami, Florida 33134, United States
  • CCR Medical Center, Suite 201
    Miami, Florida 33144, United States
  • Miami Clinical Research
    Miami, Florida 33155, United States
  • Vista Health Research, LLC
    Miami, Florida 33176, United States
  • Quantum Clinical Trials, 333 Arthur Godfrey Road, Suite 202, suite 208
    Miami Beach, Florida 33140, United States
  • Quality Research of South Florida
    Miami Lakes, Florida 33016, United States
  • Accel Research Sites Network, Ormond Clinical Research Unit, 77 West Granada Boulevard
    Ormond Beach, Florida 32174, United States
  • Clinical Research Center of Florida, 550 SW 3rd St.,, Suite #305
    Pompano Beach, Florida 33060, United States
  • Invictus Clinical Research Group, LLC
    Pompano Beach, Florida 33073, United States
  • Santos Research Center, CORP
    Tampa, Florida 33615, United States
  • Masters of Clinical Research
    Augusta, Georgia 30909, United States
  • Leavitt Clinical Research
    Idaho Falls, Idaho 83404, United States
  • Research Network America
    Berwyn, Illinois 60402, United States
  • Rush University Infectious Diseases
    Chicago, Illinois 89109, United States
  • Tandem Clinical Research
    Marrero, Louisiana 70072, United States
  • The Johns Hopkins Hospital
    Baltimore, Maryland 21287, United States
  • Infusion Associates
    Grand Rapids, Michigan 49525, United States
  • Revival Research Institute LLC
    Troy, Michigan 48312, United States
  • Las Vegas Medical Research
    Las Vegas, Nevada 89113, United States
  • AB Clinical Trials
    Las Vegas, Nevada 89119, United States
  • Renal Medicine Associates
    Albuquerque, New Mexico 87901, United States
  • Columbia University Irving Medical Center Division of Infectious Diseases
    New York, New York 10032-3722, United States
  • NY Blood Center Project ACHIEVE
    New York, New York 10065, United States
  • University of Rochester Medical Center
    Rochester, New York 14542, United States
  • Lapis Clinical Research - North State
    Denver, North Carolina 28037, United States
  • Burke Primary Care
    Morgantown, North Carolina 28655, United States
  • Progressive Medicine of the Triad, LLC
    Winston-Salem, North Carolina 27103, United States
  • Ohio State University College of Medicine
    Columbus, Ohio 43201, United States
  • Infectious Disease Clinical Trials Unit-University of Pennsylvania Health System
    Philadelphia, Pennsylvania 19104, United States
  • UPMC Eye Center - Eye and Ear Institute
    Pittsburgh, Pennsylvania 15213, United States
  • Vanderbilt Health-One Hundred Oaks
    Nashville, Tennessee 37204, United States
  • Central Texas Medical Research
    Austin, Texas 78705, United States
  • Care United Research, 375 North FM 548, suite 100
    Forney, Texas 75126, United States
  • Valley Institute of Research
    Fort Worth, Texas 76164, United States
  • Trio Clinical Trials, LLC.
    Houston, Texas 77008, United States
  • Accurate Clinical Management, LLC
    Houston, Texas 77065, United States
  • Sun Research Institute, LLC
    San Antonio, Texas 78215, United States
  • Progressive Clinical Research
    Bountiful, Utah 84010, United States
  • Clinical Research Partners LLC
    Richmond, Virginia 23226, United States
  • CINME Centro Investigaciones Metabolicas, Pres. Jose Evaristo Uriburu 754, Piso 3 dpto 12
    Ciudad Autonoma de Buenos Aires, Buenos Aires C1027AAP, Argentina
  • Sanatorio De La Trinidad, Mitre Bartolome Mitre
    Ciudad Autonoma de Buenos Aires, Buenos Aires C1039AAO, Argentina
  • Hospital Italiano sede Central, Tte. Gral. Juan Domingo Perón 4190
    Ciudad Autonoma de Buenos Aires, Buenos Aires C1199, Argentina
  • Centro Privado de Medicina Familiar, Mindout Research
    Ciudad Autonoma de Buenos Aires, Buenos Aires C1412, Argentina
  • Centro De Investigaciones
    Mar del Plata, Buenos Aires B7600FYK, Argentina
  • DIM Clínica Privada, Belgrano 136 - 5to piso
    Ramos Mejía, Buenos Aires 1704, Argentina
  • Hospital General Agudos Dr. J.M., Grl Justo José de Urquiza 609 2do piso, Pabellón Clínica Médica, Enf. Emergentes
    Ramos Mejía, Buenos Aires C1221ADC, Argentina
  • Clínicas Zárate, F. Andrade 332
    Zárate, Buenos Aires B2800DGH, Argentina
  • Sanatorio Privado ,Duarte Quiros
    Quiros, Córdoba Province 1948, Argentina
  • Instituto Médico de la, Fundación Estudios Clínicos, Italia 428, Rosario
    Rosario, Sante Fe 2000, Argentina
  • Clinica Mayo UMCB
    San Miguel de Tucumán, Tucumán Province 4000, Argentina
  • Clínica Olivos
    Buenos Aires, 1602, Argentina
  • Sanatorio Allende, Av.
    Córdoba, X5000JHQ, Argentina
  • CER San Juan,
    San Juan, 5400, Argentina
  • Mendoza 2612, Rosario
    Santa Fe, S2000PBJ, Argentina
  • SENAI CIMATEC Clinical Trial Research Center
    Salvador, Estado de Bahia 41650-010, Brazil
  • AMB3 Servicos Medicos Ltda Rua Campinas
    Cuiabá, Mato Grosso 78050-253, Brazil
  • Faculdade de Medicina da univ., Federal, Av Alfredo Balena, 190, 1° andar - sala 161
    Belo Horizonte, Minas Gerais 30130-100, Brazil
  • Hosp Nossa Senhora das Gracas, Rue Alcides Munhoz
    Curitiba, Paraná 80810-040, Brazil
  • Instituto Atena de Psequisa Clinica Ltds, Av Marechal Floriano Peixoto
    Natal, Rio Grande do Norte 59020-500, Brazil
  • Thainá Garbino dos Santos, Avenida Protásio Alves 211, Bloco C
    Porto Alegre, Rio Grande do Sul 90410-000,, Brazil
  • IPARGS, Rua Antonio Joaquim Mesquita
    Porto Alegre, Rio Grande do Sul 91350-180, Brazil
  • Fundação Pio XII - Hospital de Amor de, Barretos; Rua Antenor Duarte Villela
    Baretos, São Paulo, Brazil
  • Unid Pesquisa Clínica Facultad Medicina, de Botucatu UNESP, Rua Prof. Dr. Armando,Alves s/n, Distrito de rubião Junior
    Botucatu, São Paulo 18618-686, Brazil
  • Hospital Universario Sao Francisco, na Providencia de Deus-Av. Sao Francisco de Assis
    Bragança Paulista, São Paulo 12916-350, Brazil
  • Instituto de Pesquisa Clinica de Campinas IPECC Tua Oswaldo
    Campinas, São Paulo 13060-080, Brazil
  • Cecip Jau
    Jaú, São Paulo 17201-210, Brazil
  • Pesquisare Saude
    Santo André, São Paulo 09080-111, Brazil
  • CEMEC
    São Bernardo do Campo, São Paulo 09715-090, Brazil
  • Esperanca Clinica De Pesquisas
    São Paulo, São Paulo 01001-000, Brazil
  • Instituto de Molestast Cardiovasculares
    Tatuí, São Paulo 18273-170, Brazil
  • Hospital da Puc Campinas, Centro de Pesquisa Sao Lucas
    Campinas, 13034-685, Brazil
  • IBPClin, Rua da Gloria
    Rio de Janeiro, 20241-180, Brazil
  • INI/Fiocruz
    Rio de Janeiro, 21040-360, Brazil
  • Lóbus Cntr. de Pesquisa Cl.
    Volta Redonda, 27253-003, Brazil
  • Programa de estudios y control de, enfermedades tropicales PECET, Carrera 53 N°61-30 Torre 2, Lab. 632
    Medellín, Antioquia 050010, Colombia
  • Centro de Investigación Medico, Asistencia - CIMEDICAL S.A.S, Cra 49C # 82-120
    Barranquilla, Atlántico 080020, Colombia
  • Corazon IPS S.A.S, Carrera 49 No 74 - 158
    Barranquilla, Atlántico 080020, Colombia
  • IPS CENTRO CIENTIFICO ASISTENCIAL S.A.S, Cra 45 #85-49
    Barranquilla, Atlántico 80020, Colombia
  • Centro de investigación en Reumatología, y Especialidades Medicas S.A.S, CIREEM S.A.S.-Cra. 12#97-32
    Bogotá, Bogota D.C. 110221, Colombia
  • Fundación Centro Excelencia en Enferm., Crónicas No Transmisibles-FUNCENTRA, CRA 3 N°21 44 B,
    Chuchurubi Monteria, Departamento de Córdoba 230002, Colombia
  • TyC Inversiones SAS Grupsalud 33-6 IPS, Avenida Libertador # 30-360, Barrio San Pedro Alejandrino
    Santa Marta, Magdalena Department 470003, Colombia
  • Fundación Cardiomet Cequin,, Street 18 North # 14-25,
    Armenia, Quindío Department 630004, Colombia
  • BlueCare Salud SAS
    Bogotá, 110221, Colombia
  • Navrongo Health Research Cntr
    Upper East, Navrongo PO BOX 114, Ghana
  • Kintampo Health Research Cntr
    Kintampo, PO BOX 200, Ghana
  • Kumasi Centre for Research, South End Asuogya Road, Kwame Nkrumah University
    Kumasi, AK-312-1059, Ghana

Showing the first 100 of 196 sites across 17 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Luetkemeyer AF, Chew KW, Lacey S, Hughes MD, Harrison LJ, Daar ES, Eron J, Fletcher CV, Greninger AL, Hessinger D, Li JZ, Mailhot D, Wohl D, Chayakulkeeree M, Mendoza JLA, Elistratova P, Makinde O, Morgan G, Portsmouth S, Uehara T, Smith D, Currier JS. Ensitrelvir for the Treatment of Nonhospitalized Adults with COVID-19: Results from the SCORPIO-HR, Phase 3, Randomized, Double-blind, Placebo-Controlled Trial. Clin Infect Dis. 2025 Jul 18;80(6):1235-1244. doi: 10.1093/cid/ciaf029. PubMed 39960062 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2022 to primary completion in Jan 2024, 17 months.

Results were first posted in Aug 2026, 2 years 7 months after primary completion. A results delay was requested in Jan 2025.

Of 168 industry-sponsored phase 3 interventional studies under COVID-19, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 16. This study's 17 months is above that.

Counting every sponsor, half of 453 studies reached it within 9 months; a quarter within 4 and three quarters within 17.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 30, 2022
First posted
Mar 31, 2022
StartActual
Aug 3, 2022
Primary completionActual
Jan 7, 2024
CompletionActual
May 24, 2024
Results delay requested
Jan 2, 2025
Results first posted
Aug 20, 2026
Last update
Aug 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 20, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05305547
Lead sponsor
Shionogi
Responsible party
Sponsor
First posted
Mar 31, 2022
Start date
Aug 3, 2022
Primary completion
Jan 7, 2024
Completion
May 24, 2024
Results posted
Aug 20, 2026
Last update
Aug 20, 2026

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ensitrelvir

Start the discussion